Clinical Trials
Understanding how clinical trial data integrates into VIALLMED HUB drug rankings and performance analytics.
Clinical Trial Integration
Clinical trials are the cornerstone of pharmaceutical development and a critical factor in VIALLMED HUB CPI rankings. Success rates across trial phases provide objective measures of drug efficacy, safety, and regulatory viability.
Our platform tracks clinical trials from early-phase safety studies through large-scale Phase III trials and post-market surveillance. This comprehensive view enables accurate assessment of drug development trajectories and market potential.
Clinical Trial Phases
Initial safety testing in small groups of healthy volunteers or patients. Determines safe dosage ranges, identifies side effects, and assesses how the body processes the drug. Approximately 70% of drugs advance from Phase I.
Evaluates effectiveness for specific conditions and monitors safety in larger patient populations. Establishes optimal dosing and identifies common adverse reactions. About 33% of drugs successfully complete Phase II.
Confirms efficacy, monitors adverse reactions, and compares to standard treatments in diverse patient populations. Provides data for FDA approval decisions. Approximately 25-30% of drugs entering Phase III receive FDA approval.
Continues after FDA approval to monitor long-term effects, optimal use, and safety in real-world settings. Detects rare or long-term adverse effects and expands understanding of benefits and risks.
Trial Success Rate Impact
Average Success Rate
CPI Rating Factor
Trials Tracked
Clinical trial success rates are one of the highest-weighted factors in VIALLMED HUB CPI rankings. Drugs with consistently successful trials across phases demonstrate robust efficacy and safety profiles, significantly boosting their rankings.
How Trials Impact CPI Rankings
Phase Success Progression
Drugs that successfully advance through trial phases receive incremental CPI boosts. Completing Phase III and entering Phase IV (post-market surveillance) demonstrates exceptional clinical performance and regulatory confidence.
Comparative Trial Performance
Trials that show superiority to existing treatments or placebos with statistical significance receive higher weighting. Head-to-head comparisons demonstrating clinical advantages significantly impact rankings.
Safety Profile Integration
Low rates of serious adverse events and favorable safety profiles enhance CPI ratings. Drugs with clean safety records across large patient populations demonstrate reliability and broad applicability.
Learn More
For detailed information about how clinical trial data factors into our CPI rating algorithm, see our comprehensive Methodology page.
Questions about specific trial data or sources? Contact our research team at research@viallmedhub.com.